{"filings":[{"id":92798,"accession_number":"0001140361-26-020036","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BMY shareholders elect all 11 directors, pass say-on-pay, stock plan, auditor; independent chair proposal fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected with >1.46B votes for each.","Say-on-pay approved: 1.46B for, 72.5M against, 6.9M abstain.","2026 stock award and incentive plan approved: 1.47B for, 63.9M against.","Ratification of Deloitte & Touche as 2026 auditor: 1.71B for, 63.7M against.","Shareholder proposal for independent board chair defeated: 422M for, 1.11B against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92797,"accession_number":"0000014272-26-000008","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q1 revenue $11.5B (+3%); reaffirms 2026 guidance trending upper end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $11.5B, up 3% YoY (1% ex-FX); Growth Portfolio revenue $6.2B (+12% / +9% ex-FX).","GAAP EPS $1.31; non-GAAP EPS $1.58; both include $(0.03) net impact from Acquired IPRD and licensing.","FY 2026 guidance reaffirmed: revenue ~$46.0-47.5B, non-GAAP EPS $6.05-6.35, trending toward upper end.","CEO highlights strong execution and pipeline milestones ahead for patients and shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":11489000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103931,"accession_number":"0000014272-26-000002","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q4 rev $12.5B (+1%), non-GAAP EPS $1.26; dividend raised to $0.63/share; FY2026 guidance rev $46-47.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $12.5B (+1% YoY); Growth Portfolio rev $7.4B (+16%). Full-year rev $48.2B.","GAAP EPS Q4 $0.53, FY $3.46; Non-GAAP EPS Q4 $1.26, FY $6.15.","2026 guidance: revenue ~$46-47.5B, non-GAAP EPS $6.05-6.35.","Quarterly dividend raised to $0.63/share, 17th consecutive annual increase.","Acquired IPRD charges and licensing income net impact of $(0.60) on Q4 EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":3.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":48194000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103930,"accession_number":"0001140361-26-000929","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bristol Myers Squibb posts investor presentation at J.P. Morgan Healthcare; no specific updates in filed excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Christopher Boerner, Board Chair & CEO, presented at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.","Presentation titled 'Built for Growth' posted on company website at bms.com/investors/events-and-presentations.html.","No specific financial metrics, guidance changes, or pipeline updates are included in the filed portion of the presentation.","Filing under Regulation FD; information furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120204,"accession_number":"0001140361-25-042607","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BMY completes early settlement of ~$7.5B tender offers for 15 note series","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended Pool 1 max purchase price to ~$3.99B; Pool 2 max to ~$3.51B.","All validly tendered Pool 1 notes and Pool 2 notes (priority 1-4) accepted at 100%; 2033 notes prorated at ~50.84%.","Early Settlement Date set for November 20, 2025; no further tenders will be accepted.","Total consideration per $1,000 principal ranged from $985.66 to $1,129.13 depending on series.","Accepted notes will be cancelled and retired; interest ceases on settlement date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120203,"accession_number":"0001140361-25-041380","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BMY subsidiary issues €5B notes (2.973%-4.581%) to fund tender offer and general purposes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €5B across five tranches: €750M (2030, 2.973%), €1.15B (2033, 3.363%), €1.15B (2038, 3.857%), €750M (2045, 4.289%), €1.2B (2055, 4.581%).","Proceeds plus ~$3B cash on hand will fund a tender offer for existing BMY notes and pay fees.","Notes are fully and unconditionally guaranteed by BMY on a senior unsecured basis.","Interest payable annually on Nov 10 beginning Nov 10, 2026; optional redemption at make-whole spreads of +10 to +20 bps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120202,"accession_number":"0001140361-25-040066","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bristol-Myers Squibb launches $7B cash tender offer for 15 series of outstanding notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offers up to $4B for Pool 1 notes (2026-2029 maturities) and $3B for Pool 2 notes (2031-2097).","Early tender deadline Nov 17, 2025; expiration Dec 3, 2025; early tender premium $50 per $1,000 principal.","Financing from new debt offering by subsidiary plus ~$3B cash on hand; accepted notes will be cancelled.","Dealer managers: Citigroup, Deutsche Bank, Goldman Sachs, Morgan Stanley."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120201,"accession_number":"0000014272-25-000147","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q3 revenue $12.2B (+3% YoY), GAAP EPS $1.08, raises FY revenue guidance to ~$47.5-48B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $12,222M (+3% YoY; +2% ex-FX); Growth Portfolio $6.9B (+18% ex-FX).","GAAP EPS $1.08 (up 81% YoY); non-GAAP EPS $1.63 (down 9% YoY); both include $(0.20) net impact from Acquired IPRD and licensing.","FY 2025 revenue guidance raised to ~$47.5B-$48.0B; non-GAAP EPS expected $6.40-$6.60 (includes $(0.80) net Acquired IPRD impact).","Q3 2024 comparatives: revenue $11,892M, GAAP EPS $0.60, non-GAAP EPS $1.80.","CEO cites Growth Portfolio momentum, pipeline advancements, and strategic business development."],"consensus_eps_estimate":null,"consensus_eps_actual":2.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":35692000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136778,"accession_number":"0000014272-25-000129","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BMY Q2 revenue $12.3B, GAAP EPS $0.64, non-GAAP EPS $1.46; raises revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.3B, +1% YoY; Growth Portfolio $6.6B, +18% YoY (+17% ex-FX).","GAAP EPS $0.64 vs $0.83 YoY; non-GAAP EPS $1.46 vs $2.07 YoY, both hit by $(0.57) BioNTech IPRD charge.","2025 revenue guidance raised to ~$46.5B–$47.5B; non-GAAP EPS guidance updated to $6.35–$6.65.","BioNTech strategic partnership resulted in a $0.57 per share Acquired IPRD charge in Q2.","CEO cites strong Growth Portfolio execution, cost optimization, and pipeline partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":23470000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136777,"accession_number":"0001140361-25-027350","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bristol Myers Squibb appoints Cristian Massacesi as CMO; Samit Hirawat departs by Nov 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cristian Massacesi, M.D., named EVP, Chief Medical Officer and Head of Development, effective August 1, 2025.","Samit Hirawat, M.D., steps down as CMO and Head of Development on August 1; will remain advisor through November 1, 2025.","Massacesi will oversee early- and late-stage development across all therapeutic areas and serve on Executive Leadership Team.","Hirawat leaves after six years; company cites his role in advancing pipeline across oncology, hematology, immunology, cardiovascular, neuroscience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154000,"accession_number":"0001140361-25-017742","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BMY shareholders elect all 11 directors, approve compensation, at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected; votes 'for' ranged from 1.49B to 1.53B.","Advisory vote on executive compensation approved: 1.44B for, 92M against.","Ratification of Deloitte as auditor approved: 1.72B for, 59M against.","Shareholder proposal on corporate financial sustainability defeated: 17.6M for, 1.51B against.","Shareholder proposal to cease DEI efforts defeated: 26.5M for, 1.50B against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153999,"accession_number":"0000014272-25-000089","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol-Myers Squibb Q1 revenue $11.2B (-6% YoY), GAAP EPS $1.20, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $11.2B, down 6% (4% ex-FX) from $11.865B in Q1 2024.","Growth Portfolio revenues $5.6B, up 16% (18% ex-FX) driven by new launches.","GAAP EPS $1.20; non-GAAP EPS $1.80, compared to prior-year losses of $5.89 and $4.40 respectively.","FY 2025 revenue guidance raised to ~$45.8B-$46.8B, non-GAAP EPS raised to $6.70-$7.00.","CEO cites strong execution and pipeline progress; multi-year transformation plans on track."],"consensus_eps_estimate":null,"consensus_eps_actual":1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":11201000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172640,"accession_number":"0001140361-25-005012","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bristol-Myers General Counsel Sandra Leung to retire in 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandra Leung notified company of her retirement from EVP, General Counsel role, effective in 2025.","She will remain for a transition period until successor is appointed.","Retirement benefits will be provided under existing compensation plans.","Successor not yet named; transition expected before year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172639,"accession_number":"0000014272-25-000037","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BMY Q4 rev +8% to $12.3B, GAAP EPS $0.04; expands cost-savings by $2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenues $12.3B (+8% YoY, +9% ex-FX); GAAP EPS $0.04, Non-GAAP EPS $1.67.","Full-year 2024 revenues $48.3B (+7% YoY); GAAP loss per share $(4.41), Non-GAAP EPS $1.15.","Growth Portfolio revenues $22.6B for FY24 (+17%, +19% ex-FX); Q4 $6.4B (+21%).","Strategic productivity initiative expanded to deliver ~$2B additional cost savings by end of 2027.","2025 guidance: revenues ~$45.5B, Non-GAAP EPS range $6.55-$6.85."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":48300000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172638,"accession_number":"0001140361-25-000885","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bristol-Myers Squibb posts investor presentation at J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted on Jan 13, 2025, by CEO Christopher Boerner at the 43rd Annual J.P. Morgan Healthcare Conference.","Exhibit 99.1 contains only a title slide; no new financial data or guidance disclosed in the filing.","Filing under Item 7.01; information is furnished, not filed, per Regulation FD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189648,"accession_number":"0000014272-24-000145","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q3 2024 revenue $11.9B (+8% YoY); raises full-year guidance, Cobenfy approved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenues $11.9B, up 8% (+10% ex-FX); GAAP EPS $0.60, Non-GAAP EPS $1.80.","Growth Portfolio revenues $5.8B, up 18% (+20% ex-FX).","U.S. approval of Cobenfy (schizophrenia) achieved in Q3.","Raising 2024 revenue guidance to ~+5% (+6% ex-FX); Non-GAAP EPS range raised to $0.75–$0.95.","Net impact of acquired IPRD charges and licensing income reduced EPS by $0.09 on both GAAP and Non-GAAP."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":35958000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206137,"accession_number":"0000014272-24-000121","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q2 rev $12.2B (+9%), non-GAAP EPS $2.07, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $12.2B up 9% YoY (+11% ex-FX); Growth Portfolio $5.6B up 18% (+21% ex-FX).","GAAP EPS $0.83, non-GAAP EPS $2.07; includes $(0.04) per share net impact from IPRD and licensing.","Raising 2024 non-GAAP guidance; U.S. approvals of Breyanzi for follicular and mantle cell lymphoma.","Subcutaneous nivolumab under regulatory review in U.S. and E.U.","CEO Boerner cited progress on commercial execution and pipeline advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":24066000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223186,"accession_number":"0001140361-24-030533","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bristol Myers Squibb elects former Agilent CEO Michael McMullen to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael R. McMullen elected to board, effective July 1, 2024; board size increases to 11.","McMullen served as Agilent CEO 2015-2024, nearly tripled market cap; independent director.","He will serve on Audit Committee; receives $110k annual retainer + $210k in deferred share units."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223185,"accession_number":"0001140361-24-025213","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Bristol-Myers Squibb shareholders approve charter amendment limiting executive officer liability, elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to eliminate/limit monetary liability for breach of duty of care for specified executive officers approved by majority of outstanding shares.","All 10 director nominees elected; votes ranged from 1.38B to 1.48B 'for' with minimal 'against'.","Advisory vote on named executive officer compensation passed (1.40B for, 82.96M against).","Deloitte & Touche ratified as independent auditor for 2024 (1.71B for, 45.39M against).","Two shareholder proposals (independent board chair, executive stock retention) did not pass."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223184,"accession_number":"0000014272-24-000094","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol-Myers Squibb Q1 revenue up 5% to $11.9B; GAAP loss per share $5.89 on acquired IPRD charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenues $11,865M (+5% reported, +6% ex-FX); growth portfolio revenues $4,767M (+8%, +11% ex-FX).","GAAP loss per share ($5.89); Non-GAAP loss per share ($4.40); includes $6.30/share impact from acquired IPRD and licensing.","Completed acquisitions of Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and SystImmune collaboration.","Announced strategic productivity initiative targeting ~$1.5B in cost savings, majority reinvested for innovation.","Updated 2024 non-GAAP EPS and line-item guidance to reflect recent transactions; Abecma and Breyanzi received new U.S. approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":11865000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242679,"accession_number":"0001140361-24-013978","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bristol-Myers director Gerald Storch not seeking re-election; board size set to ten","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gerald Storch notified the Board on March 13, 2024, that he will not stand for re-election at the 2024 Annual Meeting.","Board set the number of directors at ten, effective after the Annual Meeting expected on May 7, 2024.","Storch's departure is voluntary; no replacement has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242678,"accession_number":"0001140361-24-013726","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bristol-Myers Squibb completes $330/share acquisition of Karuna Therapeutics, adds schizophrenia drug KarXT","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Each Karuna share converted into $330 cash; deal closed March 18, 2024.","Lead asset KarXT (xanomeline-trospium) has PDUFA date Sept 26, 2024 for schizophrenia.","Transaction expected to be dilutive ~$0.30 to non-GAAP EPS in 2024 from financing costs.","One-time ~$12B Acquired IPR&D charge impacts Q1 2024 GAAP/non-GAAP EPS by ~$5.93.","BMS to update financial outlook when reporting Q1 2024 results on April 25."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242677,"accession_number":"0001140361-24-009040","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["8.01","1.01","9.01"],"status":"ready","headline":"BMY closes $13.5B multi-tranche note offering to fund Karuna and RayzeBio acquisitions","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued nine tranches totaling $13.5B: Floating Rate Notes (2026) and fixed-rate notes from 2026 to 2064.","Proceeds partially fund proposed acquisitions of Karuna Therapeutics and RayzeBio; remainder for general corporate purposes.","Special mandatory redemption at 101% if Karuna deal not closed by June 30, 2025 or company abandons it (excludes 2034, 2044, 2054, 2064 notes).","Largest tranches: $2.5B 5.200% notes due 2034 and $2.75B 5.550% notes due 2054.","Underwriting syndicate includes major banks; customary covenants and events of default apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242676,"accession_number":"0001140361-24-008198","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bristol-Myers Squibb appoints Phil Holzer as Senior VP & Controller effective Feb 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Phil Holzer appointed Senior Vice President and Controller, succeeding Sharon Greenlees who will move to another role.","Holzer joined BMY in 2001; most recently served as SVP Finance, Treasury & Tax Operations (2021-2024).","Holzer holds a B.S. in Accounting from University of Tampa and is a CPA.","No family relationships or arrangements regarding his selection as an officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242675,"accession_number":"0001140361-24-008013","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BMY warns shareholders about unsolicited mini-tender offer at $55/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tutanota LLC offered $55/share for up to 500k BMY shares (<0.025% of outstanding).","Offer conditioned on BMY stock closing above $55 on offer expiry; below-market risk if met.","BMY recommends rejecting; tendered shares can be withdrawn by Feb 23, 2024.","SEC cautions that mini-tender offers often target below-market prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242674,"accession_number":"0000014272-24-000020","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q4 rev up 1% to $11.5B; Non-GAAP EPS $1.70; FY rev $45.0B; 2024 EPS guide $7.10-$7.40","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fourth quarter revenues $11.5B (+1% YoY); GAAP EPS $0.87, Non-GAAP EPS $1.70.","Full-year revenues $45.0B (-2% YoY); GAAP EPS $3.86, Non-GAAP EPS $7.51.","In-line & new product portfolio revenues: +9% in Q4, +7% in FY to $37.9B.","2024 guidance: revenue growth low single-digits; Non-GAAP EPS $7.10-$7.40 (excl. pending acquisitions).","Pipeline: FDA approval of Augtyro; Breyanzi sBLAs accepted; completed Mirati purchase, pending Karuna & RayzeBio."],"consensus_eps_estimate":null,"consensus_eps_actual":3.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":45006000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242673,"accession_number":"0001140361-24-001288","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bristol-Myers Squibb posts investor presentation for J.P. Morgan; details not in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated January 8, 2024, posted on BMS investor website.","No specific financial figures, guidance, or pipeline updates extracted from the supplied exhibit text.","Filing is a procedural notice (Item 7.01) with no material new information discernible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260062,"accession_number":"0001140361-23-059159","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bristol Myers Squibb to acquire Karuna Therapeutics for $330/share, ~$14B equity value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal valued at $14.0B equity / $12.7B net of cash; 53.4% premium to KRTX Dec 21 close.","Karuna's lead asset KarXT for schizophrenia; PDUFA date Sept 26, 2024; also in trials for Alzheimer's psychosis.","Expected to close H1 2024, subject to Karuna shareholder and regulatory approvals; financed with new debt.","Non-GAAP EPS dilutive by ~$0.30 in 2024 due to financing cost; BMS cites portfolio prioritization to offset."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260061,"accession_number":"0001140361-23-052908","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bristol-Myers Squibb completes $4.5B note offering to finance Mirati acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$4.5B note offering completed: $1B 5.75% due 2031, $1B 5.9% due 2033, $1.25B 6.25% due 2053, $1.25B 6.4% due 2063.","Proceeds to fund general corporate purposes, including the proposed acquisition of Mirati Therapeutics.","Offering closed November 13, 2023; underwritten by syndicate of banks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260059,"accession_number":"0001140361-23-050518","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K/A","filed_at":"2023-10-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bristol-Myers details CEO succession; Caforio to retire April 1, 2024, Boerner Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Giovanni Caforio steps down as CEO, becomes Executive Chairman Nov 1, 2023, then retires from Board April 1, 2024.","Christopher Boerner appointed CEO effective Nov 1, 2023; will also become Chairman on April 1, 2024.","Boerner's new package: $1.5M base salary, 150% target bonus, additional $1.6M LTI (60% PSUs, 40% MSUs).","Caforio's salary and bonus unchanged during transition; no further LTI awards after March 2024.","Board size set at 11 effective April 1, 2024, following Caforio's retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260060,"accession_number":"0000014272-23-000179","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol-Myers Q3 rev $10.97B; GAAP EPS $0.93, non-GAAP $2.00; Mirati acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $10,966M, down 2% YoY (3% ex-FX); GAAP EPS $0.93 (+24%), non-GAAP EPS $2.00 (+1%).","In-line and new product portfolio revenue grew 8% YoY (7% ex-FX).","Acquired IPRD and licensing charges reduced GAAP and non-GAAP EPS by $0.03 per share.","Planned acquisition of Mirati Therapeutics to strengthen oncology pipeline; terms not disclosed.","Adjusted 2023 GAAP EPS guidance downward; raised midpoint of non-GAAP EPS guidance range."],"consensus_eps_estimate":null,"consensus_eps_actual":2.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":33529000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277348,"accession_number":"0001140361-23-038900","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bristol-Myers Squibb enters $4B accelerated share repurchase with four banks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ASR agreements with Bank of America, Citibank, JPMorgan Chase, and Morgan Stanley to repurchase $4.0B of common stock.","On August 10, BMS pays $4B and initially receives shares worth 85% of purchase price based on Aug 9 closing price.","Final number of shares based on VWAP during term; scheduled to terminate in Q4 2023.","BMS may receive additional shares or deliver shares/cash upon final settlement.","Buyback under previously authorized multi-year share repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277347,"accession_number":"0000014272-23-000150","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BMY Q2 revenue $11.2B, GAAP EPS $0.99, non-GAAP $1.75; cuts FY guidance on Revlimid decline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $11.2B, down 6% YoY (5% ex-FX); GAAP EPS $0.99 (up 50% YoY), non-GAAP EPS $1.75 (down 9% YoY).","Revlimid decline faster than expected; FY guidance revised: revenue low single-digit decline, GAAP EPS $3.72-$4.02, non-GAAP EPS $7.35-$7.65.","In-line and new product portfolio grew 4% YoY; pipeline and regulatory milestones advanced.","Announced $4B accelerated share repurchase agreement expected to execute in Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":22563000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295244,"accession_number":"0001140361-23-022991","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Bristol-Myers appoints COO and CEO-elect; shareholders elect board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Boerner named COO effective Apr 26, 2023 and CEO effective Nov 1, 2023; elected to Board May 2, 2023.","Shareholders elected 11 directors and approved say-on-pay compensation with 1.44B votes for.","Deloitte & Touche ratified as auditor for 2023 with 1.77B votes for.","Three shareholder proposals (independent chair, non-discrimination audit, special meeting) rejected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295243,"accession_number":"0000014272-23-000102","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q1 revenue $11.3B, GAAP EPS $1.07, Non-GAAP $2.05; affirms non-GAAP guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 revenues $11.3B, down 3% YoY; in-line & new product portfolio grew 8% (10% ex-FX).","GAAP diluted EPS $1.07 (up 81% YoY); Non-GAAP EPS $2.05 (up 5% YoY).","Net impact from acquired IPRD charges and licensing income was ($0.01) per share on both GAAP and non-GAAP.","Company adjusts GAAP 2023 EPS guidance; affirms non-GAAP financial guidance for 2023.","CEO Giovanni Caforio cites strong commercial execution and milestone achievements in pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":11337000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295242,"accession_number":"0001140361-23-020605","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bristol-Myers Squibb CEO Giovanni Caforio to retire Nov 1; Christopher Boerner named CEO successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Giovanni Caforio to retire as CEO effective Nov 1, 2023; will become Executive Chairman for transition period.","Christopher Boerner appointed COO effective April 26, 2023, and CEO effective Nov 1, 2023; also to join Board.","Adam Lenkowsky appointed EVP Chief Commercialization Officer, effective immediately.","Boerner's base salary increased to $1.3M; annual target cash incentive raised to $1.56M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315812,"accession_number":"0001140361-23-009050","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bristol-Myers reports no CVR payment due for Abraxane 2022 net sales of $909M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2022 Abraxane net sales of $908,974,933 triggered no payment under Celgene CVR agreement.","Company notified trustee on Feb 23, 2023; no Net Sales Payment due per CVR terms.","CVR relates to Celgene acquisition from Nov 2019; future payments may be disclosed on BMS website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315811,"accession_number":"0000014272-23-000018","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q4 revenue $11.4B, GAAP EPS $0.95; full-year $46.2B, EPS $2.95; in-line/new product portfolio grows 7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenues $11,406M (-5% YoY); full-year $46,159M (flat YoY).","GAAP EPS: Q4 $0.95, full-year $2.95; Non-GAAP EPS: Q4 $1.82, full-year $7.70.","In-Line and New Product Portfolio revenues up 7% (12% ex-FX) Q4; full-year up 9% (13% ex-FX).","Revlimid revenues declined 32% Q4 and 22% full-year due to loss of exclusivity.","2023 GAAP and non-GAAP guidance provided reflecting continued revenue and earnings growth."],"consensus_eps_estimate":null,"consensus_eps_actual":2.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":46159000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315810,"accession_number":"0001140361-23-003577","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bristol-Myers EVP Research & Early Development Rupert Vessey to depart July 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Rupert Vessey, EVP Research and Early Development, leaves effective July 3, 2023.","Severance under Senior Executive Severance Plan; pro-rated vesting of MSUs, PSUs, and full vesting of 2019 RSU Inducement Award.","Pro-rated annual incentive payout for 2023 of $550,855.","No replacement named at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315809,"accession_number":"0001140361-23-000970","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BMY posts investor presentation for JP Morgan Conference on Jan 9, 2023","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made an investor presentation available on its website; specific content not provided in filing.","Presentation dated January 2023 and tied to JP Morgan Conference.","No financial guidance, pipeline updates, or material announcements can be confirmed from the filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334141,"accession_number":"0000014272-22-000194","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2022-10-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BMY Q3 revenue $11.2B (-3% YoY), GAAP EPS $0.75, Non-GAAP $1.99","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.2B, down 3% vs Q3 2021; U.S. revenue up 9% to $7.9B, international down 24% to $3.3B.","GAAP EPS $0.75, Non-GAAP EPS $1.99; non-GAAP excludes amortization and acquired IPRD charges.","In-line and new product portfolio grew 8% to $8.6B (13% ex-FX); Revlimid fell 28% to $2.4B.","Completed Turning Point acquisition; FDA approved Sotyktu for plaque psoriasis in September.","Adjusted 2022 GAAP EPS guidance; reaffirmed non-GAAP EPS guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":2.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":34753000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351547,"accession_number":"0000014272-22-000164","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol-Myers Q2 revenue $11.9B (+2% YoY); Non-GAAP EPS $1.93 (+18%); GAAP EPS guidance adjusted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $11.887B, up 2% (5% ex-FX); U.S. revenue +12% to $8.3B, international revenue -16% (-8% ex-FX).","GAAP EPS $0.66 (up 40%); non-GAAP EPS $1.93 (up 18%); GAAP net earnings $1.4B vs $1.1B.","In-line product revenue +11% YoY (Eliquis +16%, Opdivo +8%); Revlimid -22% on generic erosion.","New product portfolio added $257M (Abecma, Opdualag, Reblozyl); Acquired IPRD charges $400M.","2022 GAAP EPS guidance adjusted; non-GAAP EPS guidance reaffirmed; dividend maintained at $0.54/share."],"consensus_eps_estimate":null,"consensus_eps_actual":1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":23535000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368942,"accession_number":"0001140361-22-023069","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bristol-Myers Squibb elects Dr. Deepak L. Bhatt to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Deepak L. Bhatt elected to Board effective June 14, 2022; Board size increases to 11.","Dr. Bhatt will serve on the Science & Technology Committee.","He brings over 20 years of cardiovascular research experience; currently Executive Director at Brigham and Women's Hospital.","Compensation per standard non-employee director program: $105,000 annual retainer plus $200,000 DSU award."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368941,"accession_number":"0001140361-22-017866","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bristol-Myers annual meeting: all directors elected, shareholder proposals rejected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; votes ranged from 1.44B (Caforio) to 1.54B (Haller).","Advisory vote on executive compensation approved with 1.42B for, 125.7M against.","Ratification of Deloitte as auditor passed with 1.77B for, 53.4M against.","Shareholder proposal to lower special meeting threshold to 10% failed: 532.9M for, 1.01B against.","Shareholder proposal for independent board chair failed: 692.1M for, 852.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368940,"accession_number":"0000014272-22-000112","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2022-04-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol-Myers Q1 revenue $11.6B (+5%); Non-GAAP EPS $1.96 (+13%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.648B, +5% YoY (7% ex FX); U.S. revenue $7.7B (+10%).","GAAP EPS $0.59 (down 34%); Non-GAAP EPS $1.96 (up 13%); net $(0.10) Acquired IPRD impact.","In-line products +8% (Eliquis $3.2B +11%, Opdivo $1.9B +12%).","Revlimid $2.8B (-5%) and Abraxane $214M (-32%) as LOE pressures continue.","FDA approved Opdualag (melanoma) and Camzyos (cardiomyopathy) in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":11648000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368939,"accession_number":"0001140361-22-014868","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2022-04-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bristol-Myers to revise non-GAAP reporting; Q1 2022 impact of -$0.10/share from Acquired IPRD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Starting Q1 2022, non-GAAP results will include significant R&D charges from asset acquisitions and licensing, previously excluded.","2021 non-GAAP diluted EPS revised down to $7.16 from $7.51; 2020 GAAP shows new $12.5B Acquired IPRD line.","Preliminary Q1 2022 estimate: net negative impact of approx. $0.10/share from Acquired IPRD charges and licensing income.","Change follows SEC discussions; historical financials for 2020-2021 restated for comparability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388195,"accession_number":"0001140361-22-009916","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bristol-Myers appoints Sharon Greenlees as new SVP and Controller","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sharon Greenlees becomes Senior VP and Controller effective April 25, 2022; most recently at AbbVie as VP and Controller, R&D Finance.","Karen Murphy Santiago, current SVP and Controller, will depart by May 1, 2022.","Greenlees has a B.S. in Accounting and is a CPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388194,"accession_number":"0001140361-22-007672","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bristol-Myers Squibb upsizes note tender offers, accepts ~$5.15B principal, early settlement March 4","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Upsized maximum aggregate purchase price from $4.0B to accept all valid tenders; accepted ~$5.15B principal across 22 series.","Early settlement date set for March 4, 2022; interest ceases on that date for accepted notes.","Tendered notes accepted with yields ranging from 1.842% (2026 notes) to 4.122% (2097 notes) plus fixed spreads.","Some series subject to proration: 2026 Pool accepted 34.38% of tendered; 2029 Pool 69.09%; High Coupon Pool certain series prorated.","Certain high-coupon notes (4.25%, 4.625%, 4.35% due 2044–2049) not accepted due to hitting pool maximums."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388193,"accession_number":"0001140361-22-007493","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2022-03-02T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bristol-Myers Squibb issues $6B in notes across 2032-2062 maturities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Completed $6B offering: $1.75B 2.95% notes due 2032, $1.25B 3.55% due 2042, $2B 3.70% due 2052, $1B 3.90% due 2062.","Interest payable semi-annually on March 15 and September 15, beginning September 15, 2022.","Notes redeemable at option prior to applicable par call dates with make-whole spreads of 15-25 bps.","Issued under an indenture with customary covenants, restrictions, and events of default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388192,"accession_number":"0001140361-22-006591","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BMY reports 2021 Abraxane net sales of $1.18B, triggers $4.5M CVR payment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Abraxane net sales for 2021: $1,181,043,283 as recorded in BMY financial statements.","Net Sales Payment to CVR holders: approximately $4,526,082, payable by March 7, 2022.","Per CVR payment: approx $0.104592, based on record date March 6, 2022.","Payment stems from CVRs assumed in 2019 Celgene acquisition under the CVR Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-24T23:59:59+00:00|388192"}